{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sinha D"],"funding":["Princess Alexandra Research Foundation 2021 Research Award and NHMRC Investigator","This work was funded by Garnet Passe and Rodney Williams Memorial Foundation Co-joint grant (2019_CG_Gonzalez Cruz_Perry), Princess Alexandra Research Foundation 2021 Research Award and NHMRC Investigator grant (Frazer_2020).","Garnet Passe and Rodney Williams Memorial Foundation Co-joint"],"pagination":["6150"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9776741"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(24)"],"pubmed_abstract":["Immune checkpoint blockade (ICB) is now standard of care for several metastatic epithelial cancers and prolongs life expectancy for a significant fraction of patients. A hostile tumor microenvironment (TME) induced by intrinsic oncogenic signaling induces an immunosuppressive niche that protects the tumor cells, limiting the durability and efficacy of ICB therapies. Addition of receptor tyrosine kinase inhibitors (RTKi) as potential modulators of an unfavorable local immune environment has resulted in moderate life expectancy improvement. Though the combination strategy of ICB and RTKi has shown significantly better results compared to individual treatment, the benefits and adverse events are additive whereas synergy of benefit would be preferable. There is therefore a need to investigate "],"journal":["Cancers"],"pubmed_title":["Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade."],"pmcid":["PMC9776741"],"funding_grant_id":["N/A","Frazer_2020","2019_CG_Gonzalez Cruz_Perry"],"pubmed_authors":["Moseley P","Wright Q","Gabrielli B","Sinha D","Lu X","Frazer IH","Cruz JLG"],"additional_accession":[]},"is_claimable":false,"name":"Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade.","description":"Immune checkpoint blockade (ICB) is now standard of care for several metastatic epithelial cancers and prolongs life expectancy for a significant fraction of patients. A hostile tumor microenvironment (TME) induced by intrinsic oncogenic signaling induces an immunosuppressive niche that protects the tumor cells, limiting the durability and efficacy of ICB therapies. Addition of receptor tyrosine kinase inhibitors (RTKi) as potential modulators of an unfavorable local immune environment has resulted in moderate life expectancy improvement. Though the combination strategy of ICB and RTKi has shown significantly better results compared to individual treatment, the benefits and adverse events are additive whereas synergy of benefit would be preferable. There is therefore a need to investigate ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-05T14:55:05.66Z","creation":"2025-04-05T14:55:05.66Z"},"accession":"S-EPMC9776741","cross_references":{"pubmed":["36551637"],"doi":["10.3390/cancers14246150"]}}